Literature DB >> 1463117

p53 overexpression correlates with increased survival in patients with squamous carcinoma of the tongue base.

E R Sauter1, J A Ridge, J Gordon, B L Eisenberg.   

Abstract

Epidermal growth factor receptor (EGFR), transforming growth factor alpha (TGFA), and p53 are frequently overexpressed in squamous cell carcinomas (SCC) of the upper aerodigestive tract. We chose to study SCC of the tongue base, which is often advanced at presentation and fatal, to evaluate whether overexpression correlates with survival. Complete follow-up was available for 20 patients, 18 of whom had stage III or IV disease. A number of clinical (age, sex, stage of disease) and histologic (tumor grade, keratinization, mitotic rate, perineural invasion, lymphatic invasion, vascular invasion, host response) variables were analyzed. None of these variables correlated with survival. Immunohistochemical analysis was performed on paraffin-embedded tissue from each patient. Because EGFR and TGFA expression were routinely found in normal squamous epithelium, overexpression was considered present if greater uptake of the antibody was manifested by a deeper immunostain. In contrast, p53 oncoprotein was not detected in normal epithelium, so detection of the antibody was believed to indicate overexpression. EGFR was overexpressed in 60% of tumors, TGFA in 35%, and p53 in 20%. Those patients who had an overexpression of p53 had a greater mean survival than those who did not (48 versus 16 months, respectively, p = 0.06). This difference was significant for patients with clinical stage IV lesions (p = 0.03). EGFR overexpression and TGFA overexpression did not correlate with survival. p53 may serve as a biologic marker indicative of improved survival potential.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1463117     DOI: 10.1016/s0002-9610(05)80727-5

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  8 in total

1.  Head and Neck Squamous Cell Cancer: Biology (II) and Translational Methods.

Authors:  Anupam Mishra; Amita Pandey; Xiaolin Nong
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2007-10-05

Review 2.  The role of oncogenes and tumour-suppressor genes in the aetiology of oral, head and neck squamous cell carcinoma.

Authors:  J K Field
Journal:  J R Soc Med       Date:  1995-01       Impact factor: 5.344

3.  In vivo infiltration of mononuclear cells in squamous cell carcinoma of the head and neck correlates with the ability to expand tumour-infiltrating T cells in vitro and with the expression of MHC class I antigens on tumour cells.

Authors:  J Hald; N Rasmussen; M H Claesson
Journal:  Cancer Immunol Immunother       Date:  1994-12       Impact factor: 6.968

4.  Prognostic factors in resectable pancreatic cancer: p53 and bcl-2.

Authors:  R J Bold; K R Hess; A S Pearson; A M Grau; F A Sinicrope; M Jennings; D J McConkey; C D Bucana; K R Cleary; P A Hallin; P J Chiao; J L Abbruzzese; D B Evans
Journal:  J Gastrointest Surg       Date:  1999 May-Jun       Impact factor: 3.452

5.  p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma.

Authors:  H Mineta; A Borg; M Dictor; P Wahlberg; J Akervall; J Wennerberg
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

6.  The lack of correlation between proliferation (Ki-67, PCNA, LI, Tpot), p53 expression and radiosensitivity for head and neck cancers.

Authors:  T Björk-Eriksson; C M West; E Cvetskovska; M Svensson; E Karlsson; B Magnusson; N J Slevin; S Edström; C Mercke
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

7.  TP53 allele loss, mutations and expression in malignant melanoma.

Authors:  V A Flørenes; T Oyjord; R Holm; M Skrede; A L Børresen; J M Nesland; O Fodstad
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

8.  Status of p53 and p27(KIP1) in Iranian Patients With Oral Squamous Cell Carcinoma.

Authors:  Shahroo Etemad-Moghadam; Amanollah Keyhani; Kamran Yazdani; Mojgan Alaeddini
Journal:  Iran Red Crescent Med J       Date:  2015-10-19       Impact factor: 0.611

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.